Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A FIRST-IN-CLASS PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON NOVEMBER 1, 2025 THE COMPANY GRANTED RESTRICTED STOCK UNITS (RSUS) REPRESENTING 34,700 SHARES OF ITS COMMON STOCK TO THREE NEWLY-HIRED NON-EXECUTIVE EMPLOYEES. THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEES BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

AS OF A SEPTEMBER 25, 2025 DATA CUT-OFF-DATE, 10 PATIENTS WITH TREATMENT-REFRACTORY, MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WERE TREATED WITH A SINGLE DOSE OF FT819 WITH LESS-INTENSIVE OR NO CONDITIONING CHEMOTHERAPY

FATE THERAPEUTICS PRESENTS NEW CLINICAL DATA AT ACR CONVERGENCE 2025 DEMONSTRATING IMMUNE REMODELING AND DURABLE RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL THERAPY

SAN DIEGO, OCT. 02, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A FIRST-IN-CLASS PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON OCTOBER 1, 2025 THE COMPANY GRANTED TO ONE NEWLY-HIRED NON-EXECUTIVE EMPLOYEE (I) NON-QUALIFIED STOCK OPTIONS TO PURCHASE A TOTAL OF 60,000 SHARES OF THE COMPANY'S COMMON STOCK AT AN EXERCISE PRICE PER SHARE OF $1.25, WHICH WAS THE CLOSING PRICE PER SHARE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON OCTOBER 1, 2025, THE OPTIONS GRANT DATE, AND (II) RESTRICTED STOCK UNITS (RSUS) REPRESENTING 45,800 SHARES OF ITS COMMON STOCK. THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEE ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING THE OPTION VESTING ON THE ONE-YEAR ANNIVERSARY OF THE GRANT DATE AND THE REMAINING 75% VESTING IN APPROXIMATELY EQUAL MONTHLY INSTALLMENTS OVER THE FOLLOWING THIRTY-SIX MONTHS, SUBJECT TO THE EMPLOYEE BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE. THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEE BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

SAN DIEGO, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A FIRST-IN-CLASS PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON SEPTEMBER 2, 2025 THE COMPANY GRANTED (I) NON-QUALIFIED STOCK OPTIONS TO ONE NEWLY-HIRED NON-EXECUTIVE EMPLOYEE TO PURCHASE A TOTAL OF 45,000 SHARES OF THE COMPANY'S COMMON STOCK AT AN EXERCISE PRICE PER SHARE OF $1.03, WHICH WAS THE CLOSING PRICE PER SHARE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON SEPTEMBER 2, 2025, THE OPTIONS GRANT DATE, AND (II) RESTRICTED STOCK UNITS (RSUS) REPRESENTING 63,000 SHARES OF ITS COMMON STOCK TO TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES, INCLUDING THE NEWLY-HIRED EMPLOYEE RECEIVING THE NON-QUALIFIED STOCK OPTIONS REFERENCED ABOVE.THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING THE OPTION VESTING ON THE ONE-YEAR ANNIVERSARY OF THE GRANT DATE AND THE REMAINING 75% VESTING IN APPROXIMATELY EQUAL MONTHLY INSTALLMENTS OVER THE FOLLOWING THIRTY-SIX MONTHS, SUBJECT TO THE EMPLOYEE BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE. THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEES BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

FIRST PATIENT TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE FOLLOWING FLUDARABINE-FREE CONDITIONING FOR SEVERE LUPUS NEPHRITIS DEMONSTRATED DURABILITY OF RESPONSE WITH DRUG-FREE DEFINITION OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (DORIS) AT 12-MONTH FOLLOW-UP

FATE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

SAN DIEGO, AUG. 05, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A FIRST-IN-CLASS PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON AUGUST 4, 2025 THE COMPANY GRANTED (I) NON-QUALIFIED STOCK OPTIONS TO ONE NEWLY-HIRED NON-EXECUTIVE EMPLOYEE TO PURCHASE A TOTAL OF 60,000 SHARES OF THE COMPANY'S COMMON STOCK AT AN EXERCISE PRICE PER SHARE OF $1.06, WHICH WAS THE CLOSING PRICE PER SHARE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON AUGUST 4, 2025, THE OPTIONS GRANT DATE, AND (II) RESTRICTED STOCK UNITS (RSUS) REPRESENTING 60,800 SHARES OF ITS COMMON STOCK TO TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES.THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING THE OPTION VESTING ON THE ONE-YEAR ANNIVERSARY OF THE GRANT DATE AND THE REMAINING 75% VESTING IN APPROXIMATELY EQUAL MONTHLY INSTALLMENTS OVER THE FOLLOWING THIRTY-SIX MONTHS, SUBJECT TO THE EMPLOYEE BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE. THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEES BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A FIRST-IN-CLASS PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON JULY 2, 2025 THE COMPANY GRANTED (I) NON-QUALIFIED STOCK OPTIONS TO ONE NEWLY-HIRED NON-EXECUTIVE EMPLOYEE TO PURCHASE A TOTAL OF 30,000 SHARES OF THE COMPANY'S COMMON STOCK AT AN EXERCISE PRICE PER SHARE OF $1.12, WHICH WAS THE CLOSING PRICE PER SHARE OF THE COMPANY'S COMMON STOCK AS REPORTED BY NASDAQ ON JULY 2, 2025, THE OPTIONS GRANT DATE, AND (II) RESTRICTED STOCK UNITS (RSUS) REPRESENTING 37,900 SHARES OF ITS COMMON STOCK TO TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES.THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING THE OPTION VESTING ON THE ONE-YEAR ANNIVERSARY OF THE GRANT DATE AND THE REMAINING 75% VESTING IN APPROXIMATELY EQUAL MONTHLY INSTALLMENTS OVER THE FOLLOWING THIRTY-SIX MONTHS, SUBJECT TO THE EMPLOYEE BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE. THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEES BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

ALL THREE PATIENTS TREATED WITH FT819 FOLLOWING FLUDARABINE-FREE CONDITIONING REGIMEN FOR SEVERE LUPUS NEPHRITIS ACHIEVE PRIMARY EFFICACY RENAL RESPONSE (PERR); FIRST PATIENT TO REACH 1-YEAR FOLLOW-UP CONTINUES IN DRUG-FREE DEFINITION OF REMISSION IN SLE (DORIS)

FATE THERAPEUTICS ANNOUNCES UPDATED CLINICAL DATA FOR FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE DEMONSTRATING DURABILITY OF DRUG-FREE REMISSION FOR SEVERE LUPUS NEPHRITIS AT EULAR 2025 CONGRESS

SAN DIEGO, MAY 30, 2025 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED OFF-THE-SHELF CELLULAR IMMUNOTHERAPIES TO PATIENTS, TODAY ANNOUNCED THE APPOINTMENT OF MATTHEW ABERNETHY, M.B.A., TO ITS BOARD OF DIRECTORS EFFECTIVE AS OF MAY 29, 2025. MR. ABERNETHY BRINGS TO THE COMPANY OVER 15 YEARS' EXPERIENCE IN CORPORATE FINANCE AND INVESTOR RELATIONS IN THE BIOTECH AND MEDICAL DEVICE INDUSTRY. IN ADDITION, THE COMPANY ANNOUNCED THAT TIMOTHY P. COUGHLIN STEPPED DOWN FROM THE BOARD OF DIRECTORS, EFFECTIVE CONCURRENTLY WITH MR. ABERNETHY'S APPOINTMENT.

FATE THERAPEUTICS APPOINTS MATTHEW ABERNETHY, M.B.A., TO ITS BOARD OF DIRECTORS

ORAL PRESENTATION OF CLINICAL DATA FROM FT819 PHASE 1 STUDY HIGHLIGHTS SAFETY AND EFFICACY OF FLUDARABINE-FREE TREATMENT PARADIGM IN MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) ORAL PRESENTATION OF CLINICAL DATA FROM FT819 PHASE 1 STUDY HIGHLIGHTS SAFETY AND EFFICACY OF FLUDARABINE-FREE TREATMENT PARADIGM IN MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

FATE THERAPEUTICS ANNOUNCES PHASE 1 DATA PRESENTATION OF FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE FOR SLE AT EULAR 2025 CONGRESS

ADDITIONAL PHASE 1 DATA FOR FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE IN MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS TO BE FEATURED IN ORAL PRESENTATION AT EULAR 2025 CONGRESS IN JUNE

Fate Therapeutics, Inc.

FATE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Fate Therapeutics, Inc.

FATE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FATE